OTCMKTS:CMXC

Cell MedX (CMXC) Stock Price, News & Analysis

$0.03
0.00 (0.00%)
(As of 04/26/2024 ET)
Today's Range
$0.03
$0.03
50-Day Range
$0.02
$0.05
52-Week Range
$0.00
$0.93
Volume
N/A
Average Volume
25,951 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
CMXC stock logo

About Cell MedX Stock (OTCMKTS:CMXC)

Cell MedX Corp., a biotech company, discovers, develops, and commercializes therapeutic and non-therapeutic products for patients with diabetes, Parkinson's disease, high blood pressure, neuropathy, and kidney functions. It develops and manufactures eBalance Pro System for professional use by healthcare practitioners in a clinical setting; and eBalance Home System for home use for general wellness and pain management treatment, which are controlled by the eBalance Console that acts as the central controller for three pre-programmed microcurrent algorithms, including wellness, pain management, and dual. The company also develops eBalance Home and eBalance Pro System for temporary relief of shoulder, waist, back, neck, arms, and legs. The company was formerly known as Sports Asylum, Inc. and changed its name to Cell MedX Corp. in September 2014. Cell MedX Corp. was incorporated in 2010 and is headquartered in Carson City, Nevada.

CMXC Stock Price History

CMXC Stock News Headlines

The best cell phone plans in 2024
Cells, organ systems and ecosystems
Better than Bitcoin? The Biotech Stock with 46,751% Potential
4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.
CMXC Cell MedX Corp.
Cell structure - AQA Microscopes
Cell biology
Cell MedX Corp CMXC
Better than Bitcoin? The Biotech Stock with 46,751% Potential
4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.
The best cheap cell phone plans in 2023
Chemical cells
Chemical cells and fuel cells
The cell membrane
Mitosis and the cell cycle
Cells and Reproduction
Best Cell Phone Plans of 2022
FDA Submission and Corporate Update
Cell MedX names new CEO
See More Headlines
Receive CMXC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cell MedX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Sector
Medical
Industry
Medical Devices
Sub-Industry
N/A
Current Symbol
OTCMKTS:CMXC
Previous Symbol
NASDAQ:CMXC
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
N/A
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

  • Ms. Yanika Silina C.M.A. (Age 46)
    CPA, CFO, Treasurer, Corporate Secretary & Director
    Comp: $30k
  • Mr. David M. Jeffs (Age 54)
    President, CEO & Director

CMXC Stock Analysis - Frequently Asked Questions

How have CMXC shares performed in 2024?

Cell MedX's stock was trading at $0.0220 on January 1st, 2024. Since then, CMXC shares have increased by 45.5% and is now trading at $0.0320.
View the best growth stocks for 2024 here
.

What other stocks do shareholders of Cell MedX own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cell MedX investors own include Callon Petroleum (CPE), Himax Technologies (HIMX), Remark (MARK), MicroVision (MVIS), Ritter Pharmaceuticals (RTTR), Linn Energy (LINEQ), AudioEye (AEYE), Bank of America (BAC) and Celldex Therapeutics (CLDX).

How do I buy shares of Cell MedX?

Shares of CMXC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (OTCMKTS:CMXC) was last updated on 4/27/2024 by MarketBeat.com Staff

From Our Partners